Syngene has introduced its new plug and play LED lighting modules, which fit all new G:BOX and Dyversity imagers. These modules make it easy and cost-effective to enable these imagers to detect single or multiple fluorescent DNA and proteins.
PerkinElmer, Inc. launched a panel of epigenetics-based detection reagents to enable high-throughput screening for new drug candidates. The assay kits can screen for epigenetic factors to assist researching diseases such as neurodegeneration and cancer.
Warwick Analytical Service has developed a fast and precise analytical service for organisations seeking to check the purity of their samples. Warwick Analytical Service is able to investigate and precisely measure the carbon, hydrogen, and nitrogen content of samples.
Sigma-Aldrich will use its CompoZr Zinc Finger Nuclease Technology to engineer various human stem cell lines that enable tracking of differentiation to specific mature cell types via fluorescent reporters, integrated directly into developmentally expressed genes.
About 30% of breast cancer patients have tumors that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes.
In the wake of devastating cholera outbreaks in refugee camps in earthquake-wracked Haiti, a group of leading experts have urged the United States to create an emergency stockpile of cholera vaccines for future humanitarian use.
Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors.
Humans with Alzheimer's disease and mice genetically engineered to simulate it have abnormally low levels of an enzyme called EphB2 in memory centers of the brain. Improving EphB2 levels in such mice by gene therapy completely fixed their memory problems.
PerkinElmer, Inc. announced announced the release of its new cellular imaging software solution, the Columbus Scope platform, designed specifically for microscopy labs.
The Agilent Labware MiniHub from Agilent Automation Solutions is a rotating random-access device for presenting and storing SBS-format labware in laboratory automation systems.
Merrion Pharmaceuticals Plc announced the commencement of an oral drug delivery feasibility and option agreement with Rebel Pharmaceuticals, LLC, on two undisclosed compounds.
Provectus Pharmaceuticals, Inc. reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company’s Phase 2 trial of PV-10.
Trophos SA announced that recently presented data demonstrates that olesoxime, Trophos’ lead compound, is a promising candidate for neuroaxonal repair and remyelination in white matter diseases, notably multiple sclerosis.